Guangdong Hengrui Pharmaceutical Co., Ltd
49
19
26
15
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
2.0%
1 terminated/withdrawn out of 49 trials
93.8%
+7.2% vs industry average
10%
5 trials in Phase 3/4
0%
0 of 15 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (49)
A Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS-9821 Powder for Inhalation Administered as a Single Dose in Healthy Participants and Multiple Doses in Patients With COPD
Role: lead
A Phase II Trial of SHR-3045 Injection in Patients With Rheumatoid Arthritis
Role: lead
A Study on the Bioavailability of SHR-1819 Injection Administered Subcutaneously Using Different Injection Devices in Healthy Subjects
Role: lead
Clinical Study of the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Prurigo Nodularis
Role: lead
Study on the Drug Interactions of HRS-9813, Pirfenidone and Nintedanib in Healthy Subjects
Role: lead
A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis
Role: lead
A Study of SHR-1819 in Patients With Moderate-to-severe Atopic Dermatitis
Role: lead
A Study of SHR-2173 in Participants With Systemic Lupus Erythematosus
Role: lead
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SHR-4597 Inhalation in Healthy Subjects and Asthmatic Patients
Role: lead
A Study to Evaluate SHR-1139 Injection in Patients With Pyoderma Gangrenosum
Role: lead
A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics for a Single Dose of HRS-9821 Powder for Inhalation and Inhalation Suspension Administered in Healthy Subjects and Multiple Doses in Patients With COPD.
Role: lead
A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of SHR-1139 in Patients With Moderate-to-severe Active Ulcerative Colitis
Role: lead
A Phase I Study of SHR-4712 in Patients With Advanced Solid Tumors
Role: lead
A Phase I Clinical Trial of Single Subcutaneous Injection or Intravenous Infusion of SHR-1139 Injection in Healthy Chinese Subjects and Multiple Subcutaneous Injections in Patients With Moderate-to-severe Plaque Psoriasis
Role: lead
Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy
Role: lead
A Study to Assess the Efficacy and Tolerance of HRS-2261 in Subjects With Refractory Chronic Cough
Role: lead
A Study of SHR-2173 in Participants With Primary IgA Nephropathy
Role: lead
A Phase III Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis
Role: lead
Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Trial to Evaluate the Efficacy and Safety of HRS-9813 in Subjects With Pulmonary Fibrosis
Role: lead
A Study to Evaluate the Long-term Safety, Pharmacodynamics and Efficacy of SHR-1703 in Eosinophilic Asthma Patients
Role: lead